8DQ8 image
Entry Detail
PDB ID:
8DQ8
Keywords:
Title:
The structure of NicA2 variant F104L/A107T/S146I/G317D/H368R/L449V/N462S in complex with N-methylmyosmine
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-07-18
Release Date:
2023-07-26
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.17
R-Value Work:
0.14
R-Value Observed:
0.14
Space Group:
P 43
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Amine oxidase
Mutations:F104L, A107T, S146I,G317D, H368R, L449V, N462S
Chain IDs:A, B
Chain Length:432
Number of Molecules:2
Biological Source:Pseudomonas putida S16
Primary Citation
Directed evolution unlocks oxygen reactivity for a nicotine-degrading flavoenzyme.
Nat.Chem.Biol. 19 1406 1414 (2023)
PMID: 37770699 DOI: 10.1038/s41589-023-01426-y

Abstact

The flavoenzyme nicotine oxidoreductase (NicA2) is a promising injectable treatment to aid in the cessation of smoking, a behavior responsible for one in ten deaths worldwide. NicA2 acts by degrading nicotine in the bloodstream before it reaches the brain. Clinical use of NicA2 is limited by its poor catalytic activity in the absence of its natural electron acceptor CycN. Without CycN, NicA2 is instead oxidized slowly by dioxygen (O2), necessitating unfeasibly large doses in a therapeutic setting. Here, we report a genetic selection strategy that directly links CycN-independent activity of NicA2 to growth of Pseudomonas putida S16. This selection enabled us to evolve NicA2 variants with substantial improvement in their rate of oxidation by O2. The encoded mutations cluster around a putative O2 tunnel, increasing flexibility and accessibility to O2 in this region. These mutations further confer desirable clinical properties. A variant form of NicA2 is tenfold more effective than the wild type at degrading nicotine in the bloodstream of rats.

Legend

Protein

Chemical

Disease

Primary Citation of related structures